HC Wainwright Weighs in on Travere Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research report issued to clients and investors on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($1.80) per share for the year, down from their prior estimate of ($1.71). HC Wainwright currently has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Travere Therapeutics’ FY2026 earnings at $0.20 EPS and FY2027 earnings at $1.98 EPS.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.11. The business had revenue of $45.06 million for the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%.

A number of other analysts also recently weighed in on the company. Wells Fargo & Company upped their target price on Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a research report on Friday, February 16th. Wedbush reiterated an “outperform” rating and set a $13.00 target price on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Guggenheim reiterated a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Finally, Piper Sandler upped their target price on Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, January 18th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Travere Therapeutics Stock Down 2.4 %

TVTX stock opened at $5.26 on Friday. The company has a current ratio of 3.47, a quick ratio of 3.41 and a debt-to-equity ratio of 1.88. The firm has a market capitalization of $400.33 million, a PE ratio of -3.27 and a beta of 0.58. Travere Therapeutics has a 1-year low of $5.12 and a 1-year high of $22.75. The business’s 50 day simple moving average is $7.28 and its 200 day simple moving average is $7.65.

Hedge Funds Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TVTX. Armistice Capital LLC increased its stake in shares of Travere Therapeutics by 0.7% in the third quarter. Armistice Capital LLC now owns 7,500,000 shares of the company’s stock valued at $67,050,000 after buying an additional 50,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Travere Therapeutics by 10.9% in the third quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock valued at $41,727,000 after buying an additional 460,176 shares during the period. Kynam Capital Management LP increased its stake in shares of Travere Therapeutics by 105.6% in the fourth quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock valued at $17,980,000 after buying an additional 1,027,398 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Travere Therapeutics by 9.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,671,770 shares of the company’s stock valued at $14,946,000 after buying an additional 146,970 shares during the period. Finally, Finepoint Capital LP increased its stake in shares of Travere Therapeutics by 60.2% in the fourth quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock valued at $12,904,000 after buying an additional 539,500 shares during the period.

Insiders Place Their Bets

In other Travere Therapeutics news, insider Peter Heerma sold 4,195 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.53, for a total value of $35,783.35. Following the completion of the transaction, the insider now owns 99,503 shares of the company’s stock, valued at approximately $848,760.59. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Travere Therapeutics news, insider Peter Heerma sold 4,195 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.53, for a total value of $35,783.35. Following the completion of the transaction, the insider now owns 99,503 shares of the company’s stock, valued at approximately $848,760.59. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP William E. Rote sold 4,764 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.71, for a total value of $41,494.44. Following the completion of the transaction, the senior vice president now directly owns 80,720 shares of the company’s stock, valued at approximately $703,071.20. The disclosure for this sale can be found here. Insiders sold a total of 34,773 shares of company stock valued at $300,625 in the last 90 days. Corporate insiders own 3.75% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.